A series of G s protein peptidomimetics were designed and synthesised based on the published X-ray crystal structure of the active state b 2 -adrenergic receptor (b 2 AR) in complex with the G s protein (PDB 3SN6). We hypothesised that such peptidomimetics may function as allosteric modulators that target the intracellular G s protein binding site of the b 2 AR. Peptidomimetics were designed to mimic the 15 residue C-terminal ahelix of the G s protein and were pre-organised in a helical conformation by (i, i + 4)-stapling using copper catalysed azide alkyne cycloaddition. Linear and stapled peptidomimetics were analysed by circular dichroism (CD) and characterised in a membrane-based cAMP accumulation assay and in a bimane fluorescence assay on purified b 2 AR. Several peptidomimetics inhibited agonist isoproterenol (ISO) induced cAMP formation by lowering the ISO maximal efficacy up to 61%. Moreover, some peptidomimetics were found to significantly decrease the potency of ISO up to 39-fold. In the bimane fluorescence assay none of the tested peptidomimetics could stabilise an active-like conformation of b 2 AR. Overall, the obtained pharmacological data suggest that some of the peptidomimetics may be able to compete with the native G s protein for the intracellular binding site to block ISO-induced cAMP formation, but are unable to stabilise an active-like receptor conformation.
Introduction
The importance of G protein-coupled receptors (GPCRs) within drug discovery is undisputed. It is estimated that >25% of FDA approved drugs act via GPCRs. 1 However, only 27% of nonolfactory GPCRs are currently targeted by an approved drug and 15% are currently in clinical trials, leaving 232 nonolfactory GPCRs that remain entirely unexploited as drug targets.
2 Despite the central importance of GPCRs, we still have a very rudimentary understanding of the structure and function of this family of membrane-spanning receptors, particularly with respect to how GPCRs interact with intracellular proteins to achieve signal transduction and physiological responses. GPCR ligands generally bind to the extracellular side of the receptor and target the orthosteric or allosteric binding sites, or both as bivalent ligands. 3 On the other hand, the intracellular surface of GPCRs has largely been ignored in the development of allosteric modulators. Such allosteric modulators could conceivably be designed to target the receptor surface responsible for recruiting intracellular transducers such as the G proteins and arrestins and thus be useful pharmacological tool compounds for studying GPCR signal transduction and possibly provide a new avenue for drug discovery. Moreover, such compounds could be useful compounds for X-ray crystallography to stabilise GPCRs in their active state conformation, which is particularly difficult to crystallise due to the high degree of receptor exibility in the receptor active state. Recently, Leowitz and co-workers reported the discovery of an intracellular small molecule-like allosteric modulator for the b 2 -adrenergic receptor (b 2 AR) using a combinatorial approach with DNA encoded libraries. 4 The allosteric ligand was found to bind to the intracellular surface of the receptor and inhibit both G protein and arrestin mediated signalling. Kobilka and coworkers crystallised a closely related analogue of the same ligand in complex with the b 2 AR-T4 lysozyme fusion protein with the orthosteric inverse agonist carazolol bound. The structure (PDB 5X7D) clearly shows the ligand occupying the G protein binding pocket.
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Based on recent bio-structural data of active state GPCRs in complex with GPCR interacting proteins (GIP) 6, 7 or mimics thereof [8] [9] [10] [11] [12] we wondered if it would be possible to rationally design peptidomimetics that target the GIP interface. Such allosteric ligands could be benecial for stabilisation of GPCRs in various conformational states for structural studies, as pharmacological tool compounds, and could possibly provide a new avenue for therapeutic molecules. There have been some reports in the literature on using proteinogenic peptides as GPCR ligands. Hamm and co-workers have published several papers describing that peptides derived from the C-terminus of various G protein a subunits (Ga) are capable of reducing cAMP accumulation by blocking G protein coupling. [13] [14] [15] Moreover, Scheerer et al. have reported the X-ray crystal structure of rhodopsin in complex with an 11-mer C-terminal peptide from the G t protein. 10 More recently, we reported our efforts to develop a peptidomimetic that mimics the function of nanobody 80 (Nb80) a well-known allosteric modulator of the b 2 AR that binds at the same site of the receptor as the native G s protein.
9,16
Using the X-ray crystal structure of the b 2 AR in complex with the G s protein (b 2 AR-G s ) as a template (PDB 3SN6) 7 we embarked on a project to identify such allosteric modulators for the b 2 AR by a structure-based design approach.
Results and discussion

Peptidomimetic design
Hamm and co-workers previously reported that a peptide comprised of the last 12 amino acid residues from the Ga s Cterminus (Ga s CT 12 ) was capable of inhibiting G s protein coupling to the b 2 AR and increased agonist affinity for the receptor. 15 However, in our hands the corresponding proteinogenic 15-mer peptide (Ga s CT 15 ) did not block agonist induced cAMP formation in b 2 AR cell membranes, whereas Nb80 signicantly inhibited the maximal efficacy of ISO (Fig. 1c) . Whereas Hamm and co-workers used saponin-permeabilised C6 glioma cells, all peptides reported herein were evaluated in HEK293 membranes overexpressing the b 2 AR. 17 We selected to work in a cell membrane-based assay setup to render the intracellular surface freely accessible to the ligands and eliminate issues related to cell permeability. Likewise, Rasmussen Fig. 1 (a) The native Ga s CT 15 peptide sequences. Red: residues with no or weak receptor contacts. Blue: reverse turn, not helical, (b) the structure of Ga s CT 15 extracted from PDB entry 3SN6, (c) the Ga s CT 15 peptide does not inhibit agonist induced cAMP formation of the b 2 AR. Isoproterenol (ISO) concentration-response curves of cAMP accumulation were generated in the absence and presence of 50 mM peptide using HEK293 cell membranes overexpressing the b 2 AR. Data represents mean AE SEM from 3-4 independent experiments carried out in duplicates. The known b 2 AR-interacting nanobody 80 (Nb80) was included for comparison at 10 mM. 15 that showed a random coil structure (Fig. 1e) . Also, the affinity of a linear Ga s CT peptide for b 2 AR is likely signicantly lower than the full G s protein complex, which has several additional contacts with the receptor. Based on these observations, we hypothesised that it would be necessary to chemically modify the native Ga s CT 15 peptide to improve binding to the b 2 AR. In the b 2 AR-G s X-ray crystal structure the C-terminus of G s adopts an a-helix terminated by a 3-residue reverse turn (Fig. 1b) .
7 Thus, we set out to chemically modify Ga s CT 15 to preorganise the peptide in a similar conformation. Peptide stapling is a commonly applied technique for the synthesis of helical peptides. [18] [19] [20] Among the many available methods for peptide stapling we favour CuAAC-stapling between amino acids with azido-and alkynyl-modied side chains. 21, 22 This methodology was originally developed by Tornoe et al. 23 and later optimised by Table 1 Synthesis of linear and stapled peptidomimetics. Linear peptides were synthesised on 2-chlorotritylresin preloaded with leucine. The Ntermini of all peptides were acylated. Peptides 6D-9D were poorly soluble in a variety of solvent systems and were not purified/stapled. The remaining purified (or crude) linear peptides were stapled by CuAAC and purified by preparative RP-HPLC
a Yield aer preparative HPLC purication to >95% purity (non-NPC corrected). b Net peptide content (NPC) (mass% of peptide, the remainder being constituted by counter ions and water). Determined by qNMR (see ESI for details).
c Synthesised from pure linear peptide. d Synthesised from crude linear peptide. Overall yield based on resin loading.
e Presumably nished in <3 hours but le overnight for practical reasons.
Cantel et al. 24 and has been applied extensively in (i, i + 4)-peptide stapling in recent years.
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By visual inspection of the b 2 AR-G s X-ray crystal structure we concluded that the 15 C-terminal residues of Ga s participate in important interactions with b 2 AR. This is consistent with the conclusions drawn by Hildebrand and co-workers based on MD simulations. 26 In terms of design, it is important that the staple position does not disrupt binding to the target. By visual inspection and based on the MD simulation study by Hildebrand and co-workers 5 residues were identied as potential staple anchoring points (Fig. 1) . These 5 residues are ideally positioned for introduction of (i, i + 4)-staples and four stapling positions would be evaluated in the present study (Fig. 2) . Moreover, four different staple designs utilising D-and L-3-azidolysine (1-2), L-propargyl glycine (3) and O-propargylated Lserine (4) would be explored.
Synthesis
Fmoc-protected propargylglycine (3) is commercially available and the remaining azide and alkyne modied building blocks were synthesised in house. Azides 1-2 were synthesised from the corresponding Fmoc-protected amines as previously reported 27 using the diazotransfer reagent imidazole sulfonyl azide.
28,29 Alkyne 4 was synthesised in three steps from Bocprotected serine according to the published procedure.
27
Finally, for stapling positions B and D commercially available norleucine (5) was employed as a replacement for the oxidation prone methionine residue. 30 With amino acids 1-5 in hand the linear peptidomimetics 6-9 were synthesised by standard Fmocbased solid-phase peptide synthesis (SPPS) on chlorotrityl resin and the N-terminus was acylated ( Table 1 ). The synthesis of linear peptides 6-9 A-C was uneventful and they were all puried by standard preparative RP-HPLC. However, the synthesis of peptides 6D-9D where two polar residues (D and R) were replaced proved complicated due to poor solubility aer cleavage and deprotection. Because peptides 6D-9D were intended as inactive negative controls we eventually abandoned their purication and stapling due to their poor solubility, which would also translate to problems for pharmacological characterisation. Stapling of puried or crude 6-9 A-C (see ESI † for details) was carried out in t BuOH and water (1 : 2 v/v) using CuSO 4 $5H 2 O (1 eq.) and sodium ascorbate (5 eq.) as the in situ reducing agent. In general, the CuAAC reaction was clean and went to completion fast (1-3 h) to give stapled peptidomimetics 10-13 A-C that were puried by preparative RP-HPLC to >95% purity in reasonable yields. Full conversion of linear to stapled peptidomimetic was monitored by RP-HPLC by spiking the reaction sample with the linear starting material, and by FT-IR where the azide stretch (at $2100 cm À1 ) is clearly seen to disappear aer completion of the stapling reaction (see ESI †). (Fig. 2 ), the second row shows stapling position B and the third row shows a comparison of stapling position C. The columns show a comparison of the different combinations of stapling residues 1 + 3, 2 + 3, 1 + 4 and 2 + 4, respectively. The helicity of the most helical peptidomimetic 10C as determined by the induced minima at 222 nm and maxima at 190 nm was set to 100% and the helicity of all other peptidomimetics were determined relative to that of 10C.
Structural analysis by circular dichroism (CD)
All puried linear and stapled peptides were subjected to structural analysis by CD. Prior to recording CD spectra, the net peptide content (NPC) for all peptidomimetics was determined by quantitative NMR (qNMR, see ESI †). The CD data in Fig. 3 shows that stapling in general leads to peptidomimetics with a more helical structure when compared to the linear counterparts. However, the magnitude of the induced helicity varies signicantly. While the position of the staple (A, B or C, Fig. 2 ) does not have a signicant effect on the induced helicity, the employed amino acid residues (1-4) that form the staple have a tremendous effect. Employing residues 1 and 3 clearly increases the helicity of the peptide the most at all three stapling positions. The use of residues 1 and 4 likewise shows strong induction of helicity. In contrast, the use of the Damino acid 2 in combination with either 3 or 4 lowers the helical induction markedly.
Pharmacology
Membrane-based cAMP accumulation assay. Initially, the stapled peptidomimetics (10-13) and their linear precursors (6-9) were tested for their ability to modulate b 2 AR agonist-induced cAMP formation. To allow the peptidomimetics to interact with the intracellular G protein binding pocket they were tested in a membrane-based cAMP accumulation assay (see ESI †). In this setup stimulation of b 2 AR expressing membranes with various concentrations of the agonist (À)-isoproterenol (ISO) increased cAMP formation in a concentration-dependent manner (mean pEC 50 ¼ 8.64 AE 0.03). To test the effect of the peptidomimetics on the ISO-induced cAMP formation, similar ISO concentration response curves (CRCs) were generated in presence of a constant concentration of peptidomimetic (100 mM, except for 8C, which was tested at 10 mM due to poor solubility). The cAMP levels in absence of peptidomimetics were normalised to the basal (0%) and maximal efficacy (100%) of ISO in presence of vehicle (DMSO).
All peptidomimetics stapled at position A had little to no effect on the maximum efficacy of ISO ( Table 2) . Several of the peptidomimetics stapled at positions B and C displayed a small effect on the maximum efficacy of ISO; 7B, 8B, 8C and 11C all signicantly decreased the maximal efficacy to approximately 80% (Table 2 and Fig. 4) . Peptidomimetics 12B and 12C had a more pronounced effect and inhibited the maximal efficacy to $73% on average. Finally, peptidomimetic 10C affected the maximal ISO efficacy the most by lowering ISO maximal efficacy to 61%. With respect to peptidomimetic-induced effects on ISO potency, 9B and 13B signicantly decreased the potency by 39-and 8-fold, respectively, but not the efficacy of ISO (Fig. 4) . No signicant effects of the peptidomimetics were observed on the basal cAMP levels or on the Hill-slope of the tted curves.
To estimate the potency of the most efficacious peptidomimetic 10C, increasing concentrations of 10C up to 200 mM, and Table 2 Effect of G s peptidomimetics on the cAMP accumulation induced by isoproterenol (ISO) at the b 2 -adrenergic receptor (b 2 AR) in a cell membrane-based cyclic adenosine monophosphate (cAMP) accumulation assay. Basal cAMP level, maximum efficacy, pEC 50 (Àlog(EC 50 )) and Hill slope of the concentration-response curve of ISO in absence and presence of 100 mM peptidomimetic (10 mM for 8C) were calculated by non-linear regression using GraphPad Prism. Nb80 was tested at 10 mM. Data are given as mean values of n number of experiments AE SEM. Significance level P < 0.05 (*) calculated by statistical analysis with a one-way ANOVA in GraphPad Prism Nb80 as a control were applied in the presence of an ISO concentration corresponding to EC 75 . The IC 50 of 10C was estimated to 55 mM whereas the IC 50 of Nb80 was estimated to 0.40 mM (Fig. 4) .
Bimane uorescence shi assay. To further investigate their pharmacological proles, selected peptidomimetics were tested in a bimane uorescence shi assay (see ESI †). Labelling of cysteine residue 265 (C265) located in the lower part of the TM6 Fig. 4 Representative graphs of the most effective peptidomimetics on the cyclic adenosine monophosphate (cAMP) production induced by the full agonist isoproterenol (ISO) at the b 2 -adrenergic receptor (b 2 AR). The stapled peptidomimetic 10C inhibited the maximal response of ISO to 61% whereas its linear precursor 6C had no significant effect on the ISO-induced cAMP production (A). The linear 7B (B) and stapled peptidomimetic 11C (C) inhibited ISO efficacy to a smaller degree ($80%) but significantly. Their stapled (11B) and linear counterparts (7C) had a minor ($90%) albeit non-statistically significant effects. The linear 8B and stapled peptidomimetic 12B pair decreased the maximum response of ISO to 70-80% (D), which is also the case for the linear and stapled pair 8C and 12C (E). The linear 9B and stapled peptidomimetic 13B, decreased the potency of ISO by 39-and 8-fold, respectively, whereas the efficacy was not affected (F). In presence of ISO corresponding to EC 75 , the IC 50 of 10C was estimated to 55 mM, and the IC 50 of Nb80 was estimated to 0.40 mM (G). of b 2 AR with a bimane-uorophore allows detection of conformational changes associated with receptor activation. 31 Stimulation of puried, C265 uorophore-labelled b 2 AR with increasing concentrations of ISO results in a concentrationdependent decrease in the uorescence intensity (FI) and a red-shi of the maximum emission wavelength (l max ) of the bimane-uorophore probe (Fig. 5A) . The active receptor conformation may be further stabilised in the presence of G protein 31 and G protein mimetics such as Nb80. 9 Indeed, in presence of a partial equilibrium shiing ISO concentration (10 mM), Nb80 is capable of decreasing FI and red-shiing l max beyond that of ISO (10 mM) or Nb80 (5 mM) alone (Fig. 5B) . Conversely, ICI-118,551 (ICI), an inverse agonist capable of stabilising an inactive conformation of b 2 AR, blocks the 10 mM ISO-induced response and also slightly increase FI and blue-shis l max on its own (Fig. 5C) . Thus, the bimane uo-rescence shi assay can identify active and inactiveconformation stabilising ligands of the b 2 AR.
Based on the results obtained with the cAMP assay, the linear and cyclic peptidomimetic pairs 6C/10C, 7C/11C, 8C/12C, 8B/ 12B and 9B/13B were tested in the bimane assay at 20 mM (Fig. 6 ). The peptidomimetics were tested for possible effects on receptor conformation alone and in the presence of 10 mM ISO, which allows detection of peptidomimetic-induced active conformation stabilisation as seen for Nb80. Bimaneuorescence curves in presence of agonist or peptidomimetic alone or in combination were normalised to that of the receptor alone.
Unlike Nb80, none of the tested peptidomimetic were observed to stabilise an active-like conformation by decreasing FI and red-shiing l max on their own or by potentiating the response beyond that of 10 mM ISO alone. Although there was a tendency for several peptidomimetics to shi the bimaneuorescence in the opposite direction (8B, 7-8C and 10-11C), the peptidomimetics did not affect the response of 10 mM ISO alone. Interestingly, with the exception of peptidomimetic 8B only the peptidomimetics stapled at position C closest to the Cterminal were able to increase FI and blue-shi l max in a similar way to that seen for the inverse agonist ICI (Fig. 5C ).
Discussion
As anticipated CD analysis revealed that the stapled peptidomimetics generally had a higher helical content than their linear counterparts and the native Ga s 15-mer. The staples comprised of building blocks 1, 3 and 4 had the highest helical content, whereas the peptidomimetics stapled with D-amino acid 2 and alkynes 3 and 4 contained signicantly less helicity. There was no trend regarding the helical content and the stapling positions A-C.
The peptidomimetics were evaluated for their ability to block agonist-induced cAMP formation in cell membranes overexpressing the b 2 AR. Stapling the peptidomimetics at position A was not optimal for blocking cAMP formation by ISO. Thus, both stapled peptidomimetics 12A-13A and linear peptidomimetics 8A-9A were essentially inactive, indicating that this stapling position is not ideal for binding to the receptor using the present chemistry. Moving the staple towards the C-terminus (position B and C) was more favourable. The linear peptidomimetics 7B and 8B had a slight, yet signicant effect on the maximal ISO response, lowering the efficacy to approximately 80%. Stapled peptidomimetic 12B had a more pronounced effect on the maximum efficacy with a lowering to 74%. Unexpectedly the 9B/13B pair red-shied the ISO CRC comparable to that of a competitive antagonist rather than decreasing the maximal agonist efficacy as would be expected for a non-competitive antagonist. The linear 8C and stapled peptidomimetic 11C both lowered the maximum efficacy of ISO to approximately 80%. On the other hand, stapled 12C lowered the efficacy to 72%, whereas stapled 10C lowered the efficacy to approximately 61%. Thus, 10C clearly gave the most signicant decrease in the maximum efficacy of ISO. In general, the stapled peptidomimetics gave the highest reduction in efficacy and a small tendency for peptidomimetics with a high helical content to have a greater effect was observed (ESI Fig. S1 †) . Thus, stapled peptidomimetics 10C, 12B and 12C with a relatively high helical content were found to lower the efficacy the most (61-74%). However, the data also shows that a high degree of helicity on its own is not sufficient to give a notable reduction in the formation of cAMP (e.g. stapled peptidomimetic 10B).
When tested in the conformational bimane uorescence shi assay none of the peptidomimetics stabilised an active-like conformation similar to that of the G protein mimetic Nb80. However, a small tendency to increase the uorescence intensity (FI) and blue-shi l max similar to that for the inverse agonist ICI was seen. The effect was most pronounced for peptidomimetics stapled at position C but no correlation between the degree of helicity and the effect on the FI was observed. It cannot be excluded that the concentration tested in the bimane assay was too low to induce a more signicant effect. One interpretation of the obtained pharmacological data is that some of the peptidomimetics (e.g. 10C) are capable of modulating ISO-induced cAMP formation by binding to and thus overlapping with the intracellular binding site of the G protein. However, unlike Nb80, none of the peptidomimetics reported herein stabilise an active-like receptor conformation. Although only small effects of the peptidomimetics were observed it does support the idea of developing intracellular modulators of GPCR signalling derived from hotspot domains of GPCR interacting proteins (e.g. the C-termini of G proteins). However, the native C-terminal peptide sequence (Ga s CT 15 ) that was employed as a template herein clearly does not provide potent peptidomimetic analogues despite stapling these in a helical conformation. Thus, to render this class of ligands of use for pharmacological and biophysical studies signicant optimisation is required. It should be noted that the present study does not provide data that demonstrates that the peptidomimetics are binding in the intended G protein binding pocket. In principle, the peptidomimetics could be engaging the b 2 AR elsewhere. Further studies with more potent analogues will be required to determine the mode of action.
Conclusion
In the present study, a series of peptidomimetics that mimic the C-terminal a-helix of the Ga s protein were synthesised as potential allosteric modulators of the b 2 AR. The peptidomimetics were characterised pharmacologically in a cAMP accumulation assay and bimane uorescence assay. Several peptidomimetics inhibited agonist ISO induced cAMP formation by lowering the maximal efficacy of ISO up to 61%. For the most potent peptidomimetic 10C the IC 50 for blocking ISO induced cAMP formation was determined to 55 mM. Moreover, some peptidomimetics could decrease the potency of ISO signicantly (up to 39-fold). In the bimane uorescence assay none of the tested peptidomimetics could stabilise an activelike b 2 AR conformation. However, we observed a tendency to shi the bimane assay in the opposite direction for some peptidomimetics. Taken together, the data suggests that some of the peptidomimetics can compete with the native G s protein for the intracellular binding site, but are unable to stabilise an active-like receptor conformation.
To render the peptidomimetics of use as pharmacological tool compounds signicant optimisation is required to increase ligand potency. Likewise, to elucidate the mode of action for this class of ligands more potent ligands are required. To this end we are in the process of strengthening ligand-receptor interactions by substitution with natural and unnatural amino acids aided by computational design. The results from these endeavours will be reported elsewhere in due course.
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